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Background: Selecting a safe and effective antithrombotic strategy in patients with atrial fibrillation (AF) and MI poses a unique challenge; yet 
long-term comparative outcome data are limited.
Methods: We linked NSTEMI patients aged ≥65 from the CRUSADE registry to Medicare claims data to assess longitudinal outcomes. We included 
patients with AF within 1 year of MI and excluded in-hospital deaths. Multivariable Cox analysis was used to assess three years of follow-up for 
subsequent admission for major bleeding event or all cause mortality according to discharge antithrombotic strategy.
Results: Among 7,621 patients with MI and AF, 2214 (29%) were treated with aspirin alone; 2841 (37%) aspirin and clopidogrel; 563 (7%) 
warfarin alone; 1272 (17%) aspirin and warfarin; and 731 (10%) warfarin, aspirin, and clopidogrel. Relative to aspirin alone, addition of clopidogrel 
or warfarin significantly increased long-term risk-adjusted bleeding rates. Those receiving triple therapy (ASA, warfarin, clopidogrel) at discharge had 
2-fold risk of bleeding admissions. Mortality rates were similar in all groups.
Conclusion: Increasing intensity of antithrombotic therapy is associated with increased long-term bleeding risk without a difference in mortality 
among patients with AF and MI. Further research is needed to determine whether these bleeding risks are balanced by reduced ischemic events. 
Table: Adjusted bleeding and mortality risk across antithrombotic treatment groups
Bleeding Mortality
Long-term* bleeding rate 
(%)
HR** 95% CI P
Long-term* mortality rate 
(%)
HR** 95% CI P
ASA alone 6.3 Reference 55.8 Reference
ASA + CLPD 7.9 1.24 1.01-1.54 0.04 51.0 0.92 0.86-1.00 0.04
Warfarin alone 9.2 1.44 1.04-1.98 0.03 60.2 1.04 0.92-1.17 0.54
Warfarin + ASA 10.1 1.69 1.33-2.16 <.001 51.9 1.01 0.92-1.11 0.86
Warfarin + ASA + CLPD 11.8 1.95 1.48-2.58 <.001 46.7 0.94 0.83-1.07 0.35
ASA = aspirin; CLPD = clopidogrel; HR = hazard ratio; 95% CI = 95% confidence interval.
* indicates unadjusted rates. ** ASA is comparator group
